Tetratherix

Tetratherix FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Tetratherix (TTX.AX) as of Oct 22, 2026 is 34.65 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 101.62 % — a change of -65.90% (lower).

FCF Conversion

34.65 %

YoY

-65.90%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Tetratherix is 2025 34.65 % . FCF Conversion Rate (FCF/EBITDA) of Tetratherix was 2024 101.62 % . It decreases by -65.90% lower compared to the previous year.

The Tetratherix FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2023
21.60 AUD
Jan 1, 2024
101.62 AUD
Jan 1, 2025
34.65 AUD
The Tetratherix FCF Conversion history
YEARFCF ConversionYoY
34.65 %-65.90%
101.62 %+370.45%
21.60 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tetratherix Stock analysis

What does Tetratherix do? Tetratherix Ltd. develops a biostealth fluid matrix for regenerative medicine, creating injectable products that form 3D matrices upon physiological temperature exposure. The company's biomaterial platform uses polymer programming for implantable solutions, with Tegenix and TegenEOS serving as carriers mixed with bone graft materials for dental, oral, and orthopedic applications. TetraDerm products address surgical incision sites to minimize scarring, while Tutelix functions as a spacer to mitigate radiation therapy side effects in prostate cancer. The firm's manufacturing center in Sydney handles cleanroom production of these medical solutions. The company's revenue streams come from selling Tegenix, TegenEOS, TetraDerm, and Tutelix products to healthcare providers, hospitals, and medical device distributors specializing in regenerative medicine. These products target clinical segments including dental procedures, orthopedic surgery, and oncology treatments. Tetratherix's injectable fluid matrix technology differentiates its offerings by enabling tissue integration without causing bodily damage during application, supporting its positioning in the regenerative medicine market. Tegenix and TegenEOS are marketed as complementary solutions for bone graft applications, while TetraDerm focuses on post-surgical scar reduction. Tutelix specifically addresses radiation therapy side effects in prostate cancer patients. The company's manufacturing center in Sydney ensures quality production of these medical products, which are distributed to healthcare professionals across dental, orthopedic, and oncology fields. Tetratherix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tetratherix stock

FCF Conversion Rate (FCF/EBITDA) of Tetratherix is 34.65 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Tetratherix changed from 101.62 % to 34.65 %, representing a -65.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Tetratherix since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Tetratherix with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Tetratherix

All Key Metrics — Tetratherix